Legend Biotech Corp ADR (NQ: LEGN )
46.06 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Headline News about Legend Biotech Corp ADR
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...
The Latest Analyst Ratings for Legend Biotech
January 24, 2023
4 Analysts Have This to Say About Legend Biotech
December 20, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
December 06, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
November 02, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148...
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following